Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
about
Current global status & impact of human papillomavirus vaccination: Implications for IndiaEffect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine TrialOral sex and oropharyngeal cancer: The role of the primary care physicians.Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa RicaCross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010.Association Study between Cervical Lesions and Single or Multiple Vaccine-Target and Non-Vaccine Target Human Papillomavirus (HPV) Types in Women from Northeastern BrazilSignificantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.Vaccination Programs for Endemic Infections: Modelling Real versus Apparent Impacts of Vaccine and Infection Characteristics.An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights from the HPV Vaccine in CanadaLess than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles.Cervical cancer: A comprehensive approach towards extermination.Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis.HPV vaccination initiation after the routine-recommended ages of 11-12 in the United States.HPV genotypes co-infections associated with cervical carcinoma: Special focus on phylogenetically related and non-vaccine targeted genotypes.Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline.Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions.Proposal for cervical cancer screening in the era of HPV vaccination.Human Papillomavirus Vaccination: Making Sense of the Public ControversyHuman papillomavirus vaccination for men: advancing policy and practice
P2860
Q28079776-18356906-9B30-4B9D-B137-F0AF17AE6AD0Q28607942-B6AA25BE-5B3C-474A-807E-9F38EC607080Q30248928-98A96DBD-C848-4E7C-ADA7-720B9A102E7DQ30300329-6C1AD892-93BD-477F-A2C8-E4907AEAB86EQ30353668-D973C612-2314-4D10-B4F6-2BB5AE67B9E2Q30354637-0496CA52-E828-4999-97DF-E9A7A82856AAQ35437586-46174EE4-AA78-43B4-A294-631EF853FE17Q35691927-74C7031F-EE0B-4567-90FD-1E593DD19ED1Q36092294-55CE2CA9-555E-4C7B-9072-E1D52DA2F377Q36180041-D9FD1AA6-C22C-4578-BE11-7F036825243EQ36652379-DE13A4EA-C1B8-45F1-8EF6-4C66583C129FQ37135074-32109673-28EA-4BB5-A8C6-D9AE4D9522FEQ37609451-2B873F79-81AB-43FF-8712-DA6AA684FA6BQ38423724-BCAD1B82-56AC-4A24-926F-C70AF799F5B1Q38748682-93DBF79D-95CC-4FB2-ACC7-E1D54B2406DAQ38906082-26E3544A-4FC3-4892-BB4D-DE96759C03E2Q40050669-CCEF76BD-408A-4E0C-93A1-3FC306806648Q40090268-B451916D-316D-4CB4-B0BF-BEC5244018C1Q46257079-FD481591-A860-43A9-B90F-6F4D47D9E5BDQ47111040-04837AEC-B3D1-4681-A5F0-9015007F64B5Q47547829-88BB7191-06A8-4C55-9B26-A26244B0678AQ55398396-9A572F5E-A6ED-4857-80C1-037EA962C15DQ57089326-AEE1F2CE-8182-4638-B65B-1F38EAE0B044Q58452367-ACB51F35-5E15-4E5D-9F42-2899FEDCCE12
P2860
Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy of the HPV-16/18 vacc ...... Rica HPV-16/18 vaccine trial.
@ast
Efficacy of the HPV-16/18 vacc ...... Rica HPV-16/18 vaccine trial.
@en
Efficacy of the HPV-16/18 vacc ...... Rica HPV-16/18 vaccine trial.
@nl
type
label
Efficacy of the HPV-16/18 vacc ...... Rica HPV-16/18 vaccine trial.
@ast
Efficacy of the HPV-16/18 vacc ...... Rica HPV-16/18 vaccine trial.
@en
Efficacy of the HPV-16/18 vacc ...... Rica HPV-16/18 vaccine trial.
@nl
prefLabel
Efficacy of the HPV-16/18 vacc ...... Rica HPV-16/18 vaccine trial.
@ast
Efficacy of the HPV-16/18 vacc ...... Rica HPV-16/18 vaccine trial.
@en
Efficacy of the HPV-16/18 vacc ...... Rica HPV-16/18 vaccine trial.
@nl
P2093
P2860
P1433
P1476
Efficacy of the HPV-16/18 vacc ...... Rica HPV-16/18 vaccine trial.
@en
P2093
Frank Struyf
Gary Dubin
Gregory Catteau
Rolando Herrero
P2860
P304
P356
10.1016/J.VACCINE.2014.06.038
P407
P577
2014-07-10T00:00:00Z